Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry

维多利祖马布 医学 乌斯特基努马 克罗恩病 外科 内科学 疾病 英夫利昔单抗
作者
Míriam Mañosa,A Fernández-Clotet,Pilar Nos,María Dolores Martin‐Arranz,Noemí Manceñido,Ana Yaiza Carbajo,Esther Hinojosa,Alejandro Hernández-Camba,Roser Muñoz-Pérez,Marta Maia Boscá-Watts,Marta Calvo,Mónica Sierra‐Ausín,E Sánchez-Rodríguez,Manuel Barreiro‐de Acosta,Alejandro Núñez-Alonso,Yamile Zabana,Lucía Márquez,Javier P. Gisbert,Jordi Guardiola,Empar Sáinz,Pedro Delgado‐Guillena,David Busquets,Manuel Van Domselaar,Eva Girona,R Lorente,Diego Casas Deza,José María Huguet,Sergio Maestro,M. José Cabello,Jesús Castro,Marisa Iborra,Fiorella Cañete,Margalida Calafat,Eugeni Domènech
出处
期刊:Digestive and Liver Disease [Elsevier BV]
卷期号:55 (1): 46-52 被引量:24
标识
DOI:10.1016/j.dld.2022.07.013
摘要

Abstract

Background

Anti-TNF agents are the only effective biological agents for the prevention of postoperative recurrence (POR) in Crohn's disease (CD). However, they are contraindicated or have been shown to fail in some patients. Although ustekinumab and vedolizumab were licensed for CD some years ago, data in this setting are scarce.

Methods

All CD patients in whom ustekinumab or vedolizumab was prescribed for the prevention of POR within three months of ileocolonic resection with anastomosis were identified from the ENEIDA registry. The development of endoscopic, clinical and surgical POR was registered.

Results

Forty patients were treated for the prevention of POR with ustekinumab and 25 were treated with vedolizumab. Eighty per cent had at least one risk factor for POR (prior resections, active smoking, perianal disease or penetrating disease behaviour). All the patients had been exposed to anti-TNF therapy. After a median follow-up of 17 and 26 months, the cumulative probability of clinical POR at 12 months after surgery was 32% and 30% for ustekinumab and vedolizumab, respectively. Endoscopic assessment within the first 18 months after surgery was available for 80% of the patients on ustekinumab and 70% for those on vedolizumab. The rate of endoscopic POR was 42% for ustekinumab and 40% for vedolizumab. One patient treated with ustekinumab and two with vedolizumab underwent a new intestinal resection.

Conclusions

Ustekinumab and vedolizumab seem to be effective in the prevention of POR in patients at high risk. Our results warrant controlled trials comparing these drugs with conventional therapies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
King完成签到 ,获得积分10
刚刚
4秒前
xiahaijun发布了新的文献求助10
5秒前
5秒前
orixero的应助被66采纳,获得10
5秒前
5秒前
linaoctcn完成签到,获得积分10
6秒前
无聊的剑心完成签到,获得积分10
6秒前
jinxli完成签到 ,获得积分10
7秒前
李健的应助被昨天想睡觉采纳,获得10
7秒前
8秒前
郸郸完成签到,获得积分10
8秒前
ho完成签到 ,获得积分10
9秒前
上山石头完成签到,获得积分10
9秒前
俏皮的姣完成签到,获得积分10
9秒前
10秒前
大个的应助被zizi采纳,获得10
10秒前
chew关注了科研通微信公众号
10秒前
开朗天问发布了新的文献求助10
10秒前
笑林完成签到 ,获得积分0
10秒前
年年年年完成签到,获得积分10
10秒前
柔弱的御姐完成签到,获得积分10
11秒前
郸郸发布了新的文献求助10
12秒前
makabaka发布了新的文献求助10
12秒前
12秒前
12秒前
12秒前
13秒前
无奈柚子发布了新的文献求助10
15秒前
科研完成签到,获得积分10
15秒前
17秒前
giA发布了新的文献求助10
18秒前
科研通AI6.4的应助被pigeon采纳,获得10
18秒前
xieyan1123完成签到,获得积分10
20秒前
21秒前
ruuu发布了新的文献求助10
21秒前
图假期小主完成签到 ,获得积分10
21秒前
www发布了新的文献求助10
22秒前
cdercder的应助被缺粥采纳,获得10
22秒前
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190478
求助须知:如何正确求助?哪些是违规求助? 9577686
关于积分的说明 21853808
捐赠科研通 7789496
什么是DOI,文献DOI怎么找? 3436407
关于科研通互助平台的介绍 2560235
邀请新用户注册赠送积分活动 2483054